NASDAQ: SLRNAcelyrin Inc Stock Ownership - Who owns Acelyrin?
Insider buying vs selling
Have Acelyrin Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Mina Kim | Chief Executive Officer | 2025-03-17 | 17,986 | $2.74 | $49.35kSell |
| Shephard Mpofu | Chief Medical Officer | 2025-03-17 | 3,211 | $2.74 | $8.81kSell |
| Amar Murugan | Chief Legal Officer | 2025-03-17 | 3,913 | $2.74 | $10.74kSell |
| Daniel J. Becker | Director | 2024-07-17 | 1 | $6.86 | $6.86Sell |
| Sanam Pangali | CLO Head of People | 2024-05-15 | 921 | $4.47 | $4.12kSell |
| Melanie Gloria | Chief Operating Officer | 2024-05-15 | 10,298 | $4.47 | $46.03kSell |
| Mina Kim | Chief Executive Officer | 2024-05-15 | 10,230 | $4.47 | $45.73kSell |
SLRN insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when SLRN insiders and whales buy or sell their stock.
SLRN Shareholders
What type of owners hold Acelyrin Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| T Rowe Price Investment Management Inc | 12.78% | 12,872,124 | $29.35M | Institution |
| Beth C. Seidenberg | 9.78% | 9,850,729 | $22.46M | Insider |
| Westlake Biopartners Fund II LP | 9.72% | 9,790,729 | $22.32M | Insider |
| Ayurmaya Capital Management Company LP | 9.27% | 9,334,735 | $21.28M | Insider |
| Ayurmaya Capital Management Company LP | 9.27% | 9,334,735 | $21.28M | Institution |
| Blackrock Inc | 5.98% | 6,020,868 | $13.73M | Institution |
| Millennium Management LLC | 4.68% | 4,714,402 | $10.75M | Institution |
| Citadel Advisors LLC | 4.18% | 4,211,916 | $9.60M | Institution |
| Vanguard Group Inc | 4.05% | 4,080,010 | $9.30M | Institution |
| Orbimed Advisors LLC | 3.97% | 4,001,711 | $9.12M | Institution |
SLRN vs Biotech Stocks
Acelyrin Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.